School of Medicine

Wayne State University School of Medicine

Profile

Elisabeth Heath, M.D. FACP
Professor - Clinical
Hematology-Oncology
Karmanos Cancer Institute
4100 John R.
4 Hudson-Webber Cancer Research Center
Mail Code: HW04HO
Detroit, MI 48201
Phone: (313) 576-8715
Fax: (313) 576-8767
EDUCATION TRAINING

Education
(1989-1993)  M.D., Jefferson Medical College, Philadelphia, PA
(1985-1989)  B.S., Molecular Biology, Lehigh University, Bethlehem, PA

Postgraduate Training
(1996-1999)  Fellowship in Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD
(1994-1996)  Residency in Internal Medicine, Georgetown University Hospital, Washington, DC
(1993-1994)  Internship in Internal Medicine, Georgetown University Hospital, Washington, DC

PROFESSIONAL EXPERIENCE

Faculty Appointments
(2013-Present)  Professor, Department of Oncology, Faculty Position, Clinical-Educator Track, Wayne State University, Karmanos Cancer Institute, Detroit, MI
(2010-2013)  Associate Professor, Department of Oncology, Faculty Position, Clinical-Educator Track, Wayne State University, Karmanos Cancer Institute, Detroit, MI
(2007-2010)  Associate Professor, Internal Medicine, Medical Oncology, Faculty Position, Clinical-Educator Track, Wayne State University, Karmanos Cancer Institute, Detroit, MI
(2003-2007)  Assistant Professor, Internal Medicine, Medical Oncology, Faculty Position, Clinical Educator Track, Wayne State University, Karmanos Cancer Institute, Division of Hematology/Oncology Detroit, MI
(2000-2003)  Assistant Professor, Medical Oncology, Faculty Position, Research Track, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD
(1999-2000)  Instructor, Medical Oncology, Faculty Position, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Hospital or Other Professional Appointments
(2015-Present)  Chair, Genitourinary Oncology Multidisciplinary Team, Karmanos Cancer Center, Detroit, MI
(2010-Present)  Director, Prostate Cancer Research, Karmanos Cancer Institute, Detroit, MI
(2006-Present)  Medical Director of the Infusion Center, Karmanos Cancer Center, Detroit, MI
(2003-Present)  Medical Oncologist, Karmanos Cancer Institute, Detroit, MI
(2010-2011)  Medical Director of the Wertz Clinic, Karmanos Cancer Center, Detroit, MI
(2001-2003)  Medical Oncologist, Virginia Oncology Associates, Virginia Beach, VA

MAJOR PROFESSIONAL SOCIETIES

American Society of Clinical Oncology
American Association for Cancer Research
Southwest Oncology Group #33548

BOARD CERTIFICATION

(2003-Present)  License to Practice Medicine, State of Michigan
(1998-2018)  Diplomate, Medical Oncology
(1996-2016)  Diplomate, Internal Medicine 

HONORS AND AWARDS

(2015)  The Wyane State University College Teaching Award
(2015)  Top Doc-Hour Magazine
(2015)  Ambassador Magazine 2015 Top Doc
(2014)  Top Doc-Hour Magazine
(2014)  First Place Karmanos Cencer Center H.E.A.R.T Tribute
(2014)  The Wayne State University College Teaching Award
(2014)  Hartmann Endowed Chair for Prostate Cancer Research
(2013)  Top Doc-Hour Magazine
(2012)  Top Doc-Hour Magazine
(2011)  Wayne State Physician Golden Heart Faculty Award
(2011)  Top Doc-Hour Magazine         
(2011)  Blue Cross Blue Shield of Michigan Foundation McDevitt Excellence in Research Award
(2011)  The Wayne State University College Teaching Award      
(2010)  Top Doc- Hour Magazine
(2012)  The Spirit of Detroit Award
(2010)  NCI Cancer Clinical Investigator Team Leadership Award
(2009)  The Leonard Tow 2009 Humanism in Medicine Award
(2007)  The Wayne State University College Teaching Award
(2007)  The Alfred P. Gold Humanism Society
(2006)  The Academy Fellowship, The Advisory Board, Washington, D.C.
(1999)  Johns Hopkins Cancer Center 1999 Fellow Research Day Poster Session, Honorable Mention for Clinical Research
(1996)  Alpha Omega Alpha
(1989)  Magna Cum Laude University Graduate
(1989)  College Scholar
(1988)  Phi Beta Kappa

COURSES TAUGHT

CB 7210: Fundamentals of Cancer Biology
CB 7240: Cancer Chemotherapy
Medical Resident Instruction

RESEARCH INTERESTS

Dr. Elisabeth Heath is an active scientific member of the Karmanos Cancer Institute (KCI) since 2003. As Professor of Oncology, her research focus is conducting clinical and translational research trials in genitourinary malignancies. Dr. Heath is the Director of Prostate Cancer Research and leads the Prostate Cancer Research Team at KCI.  She is also the Medical Director of the Infusion Center at the Karmanos Cancer Center.  Dr. Heath is currently the Principal Investigator of the Department of Defense grant supporting Karmanos Cancer Institute/Wayne State University involvement in the nationally recognized Prostate Clinical Trials Cancer Consortium.  She has also served on the Scientific Program Committee of the Developmental Therapeutics-Molecular Therapeutics Committee of the American Society of Clinical Oncology (ASCO) and has served as Program Faculty for the annual Genitourinary ASCO as well as the annual ASCO meetings.  She also currently serves as the President-Elect for the KCI Medical Executive Committee, serves on the KCI Salary Committee, is a member of the Executive Committee of the Faculty Senate of the Wayne State University School of Medicine, and serves on the Board of Directors of the Michigan Cancer Consortium.  Dr. Heath has been the recipient of the National Cancer Institute Clinical Investigator Team Leadership Award in 2010.  She has also been awarded the Wayne State University School of Medicine College Teaching Award in 2007 and 2011 as well as holds the Top Doc designation in Hour Magazine in 2010, 2011 and 2012.  Dr. Heath serves as the Faculty Advisor for the Gold Humanism Honor Society and has been the recipient of the Leonard Tow 2009 Humanism in Medicine Award.  She is the recipient of the Wayne State University School of Medicine Physician's Golden Heart Award in 2011.  Dr. Heath is a dedicated clinician, researcher, and teacher at Wayne State University. 

PUBLICATIONS

1. Cho WJ, Oliveira DS, Najy AJ, Mainetti LE, Aoun HD, Cher ML, Heath E, Kim HR, Bonfil RD. Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients. J Transl Med. 2016 Mar 15;14(1):72. doi: 10.1186/s12967-016-0829-5. PMID: 26975354
(Contribution to revising the article critically for important intellectual content and final approval of the version to be published)(Impact Factor: 3.93) 

2. Kyriakopoulos CE, Heath EI, Eickhoff JC, Kolesar J, Yayehyirad M, Moll T, Wilding G, Liu G. A multicenter phase 1/2a dose-escalation study of the antioxidant moiety of vitamin E 2,2,5,7,8-pentamethyl-6-chromanol (APC-100) in men with advanced prostate cancer. Invest New Drugs. 2016 Feb 29. [Epub ahead of print] PMID: 26924129
(Contribution to revising the article critically for important intellectual content and final approval of the version to be published)(Impact Factor: 2.919)

3. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Feb 22. pii: JCO642702. [Epub ahead of print] PMID: 26903579
(Contribution to revising the article critically for important intellectual content and final approval of the version to be published)(Impact Factor: 17.879)

4. Bruce JY, LoRusso PM, Goncalves PH, Heath EI, Sadowski E, Shalinsky DR, Zhang Y, Traynor AM, Breazna A, Ricart AD, Tortorici M, Liu G. A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors.
Cancer Chemother Pharmacol. 2016 Jan 20. [Epub ahead of print] PMID: 26791870
(Contribution to revising the article critically for important intellectual content and final approval of the version to be published)(Impact Factor: 2.765)

5. Thakur MK, Heilbrun LK, Sheng S, Stein M, Liu G, Antonarakis ES, Vaishampayan U, Dzinic SH, Li X, Freeman S, Smith D, Heath EI. A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a prostate cancer clinical trials consortium (PCCTC) study. Invest New Drugs. 2015 Nov 18. [Epub ahead of print]  PMID:26581400
(Substantial contribution to conception and design, revising the article critically for important intellectual content, and final approval of the version to be published, serving as senior author to first author hematology-oncology fellow)(Impact Factor: 2.919)

6. Vaishampayan U, Shevrin D, Stein M, Heilbrun L, Land S, Stark K, Li J, Dickow B, Heath E, Smith D, Fontana J. Phase II trial of carboplatin, everolimus and prednisone in metastatic castrate resistant prostate cancer pretreated with docetaxel chemotherapy: A
7. Prostate Cancer Clinical Trial Consortium Study. Urology. 2015 Sep 12. pii: S0090-4295(15)00798-0. doi: 10.1016/j.urology.2015.08.008. [Epub ahead of print] PMID: 26375845
(Contribution to revising the article for important intellectual content, patient contribution, and final approval of the version to be published)(Impact Factor: 2.365)

8. Bernardo MM, Kaplun A, Dzinic SH, Li X, Irish J, Mujagic A, Jakupovic B, Back JB, Van Buren E6 Han X, Dean I, Chen YQ, Heath E, Sakr W, Sheng S. Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity. Cancer Res. 2015 Jul 24. pii: canres.0234.2015. [Epub ahead of print] PMID: 26208903
(Contribution to revising the article for important intellectual content, patient contribution, and final approval of the version to be published)(Impact Factor: 9.329)

9. Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S, Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F, Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW, Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P, de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL, Chinnaiyan AM. Integrative clinical genomics of advanced prostate cancer. Cell. 2015 May 21;161(5):1215-28. doi: 10.1016/j.cell.2015.05.001. PMID: 26000489
(Contribution to revising the article for important intellectual content, patient contribution, and final approval of the version to be published)(Impact Factor: 33.116)

10. Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM Jr. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 Apr 6. pii: JCO.2014.59.4127. [Epub ahead of print] PMID: 25847934
(Contribution to revising the article for important intellectual content, patient contribution, and final approval of the version to be published)(Impact Factor: 17.879)